Hims & Hers Faces Securities Class Action After FTC Lawsuit, Adding Legal Overhang to Existing Regulatory Risks

What happened

Hims & Hers Health now faces a securities class action lawsuit filed by Hagens Berman, following the FTC's complaint that alleged serious business misconduct and drove the stock sharply lower. The class action seeks to represent investors who suffered substantial losses, but it does not introduce new factual allegations beyond those already disclosed in the FTC action. The company's filings already acknowledged the FTC litigation, and the stock had already reacted to the FTC complaint with a 15% single-day decline on July 29, 2026. This incremental legal development prolongs uncertainty and could distract management, but it does not change the core operational or financial challenges already reflected in the DeepValue report. The report's WAIT rating and $22 attractive entry remain appropriate, as the class action is a derivative of the FTC case rather than a new fundamental shock.

Implication

The class action reinforces that regulatory and legal risks are concrete and could result in financial penalties, operational restrictions, or reputational damage, all of which could impair customer acquisition and retention. Investors should monitor the progression of both the FTC case and the class action, and require a wider margin of safety—likely a price near $22—before establishing a position. The ongoing legal uncertainty, combined with the already strained branded GLP-1 transition and working capital deterioration, means the risk-reward is not yet attractive at $27.70. A successful resolution of the FTC matter without material remedies, alongside improved gross margin and cash conversion, would be needed to upgrade the thesis.

Thesis delta

The core thesis is unchanged: Hims must prove branded GLP-1 economics, normalize working capital, and contain FTC remedies. The securities class action is a foreseeable consequence of the FTC complaint and does not alter the fundamental valuation drivers. However, it increases the probability of legal distractions, potential damages, and prolonged uncertainty, which reinforces the WAIT rating and the need for a lower entry price.